PainReform Ltd Ordinary Shares PRFX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRFX is a good fit for your portfolio.
News
-
PainReform Announces Closing of $4 Million Public Offering
-
PainReform Announces Pricing of $4 Million Public Offering
-
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
-
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
-
PainReform Provides Year-End Business Update
Trading Information
- Previous Close Price
- $0.84
- Day Range
- $0.81–0.85
- 52-Week Range
- $0.69–26.41
- Bid/Ask
- $0.81 / $0.85
- Market Cap
- $2.10 Mil
- Volume/Avg
- 15,545 / 151,358
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.painreform.com
Valuation
|
Metric
|
PRFX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PRFX
Financial Strength
|
Metric
|
PRFX
|
|---|---|
Quick Ratio | 3.35 |
Current Ratio | 4.07 |
Interest Coverage | — |
Quick Ratio
PRFX
Profitability
|
Metric
|
PRFX
|
|---|---|
Return on Assets (Normalized) | −96.91% |
Return on Equity (Normalized) | −117.56% |
Return on Invested Capital (Normalized) | −120.71% |
Return on Assets
PRFX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Gywrjfxbz | Crrlh | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Sdlzfpzqql | Tpwt | $68.9 Bil | |
HLN
| Haleon PLC ADR | Kgzsvyd | Nvxvt | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xcmctccy | Sdc | $14.8 Bil | |
VTRS
| Viatris Inc | Gydttgy | Vxk | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Lvkmvrp | Dlz | $11.9 Bil | |
CTLT
| Catalent Inc | Lsbqbkrlc | Gyvjg | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Ndfwwmg | Csnq | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Grbyphz | Lfh | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Tcfyvynw | Ypfwztq | $3.5 Bil |